Table 3. Proportions of natural HC20_373 isolates in individual countries.
| Country | Criterion for further testing | Dates | Source | Number (percentage of all isolates) |
|---|---|---|---|---|
| Ireland (Republic)a | B/15 (PFGE) | 2004–2020 | Human | 17/1911 (0.7%) |
| Taiwan | STX.0170 (PFGE) | 2005–2017 | Human | 9/33,851 (0.03%) |
| Denmark | (MLVA)b | 2007–2009 | Human | 2/8000 (0.05%) |
| Ecuadorc | HC20_3 73 | 2018–2019 | Poultry, Swine, others | 6/896 (0.67%) |
| France | HC20_373 | 2014–2021 | Human, others | 6/22,333 (0.03%) |
| UK | HC20_373 | 2014–2020 | Human | 74/51,853 (0.14%) |
| United States (FDA) | HC20_373 | 2007–2018 | All isolates | 80/23,473 (0.34%) |
aBased on data within EnteroBase for all S. enterica that were isolated in Ireland between 1997 and 2018, HC20_373 strains consisted 0.6% (17/2799) of S. enterica that were isolated from humans and 0.1% (2/1822) of isolates from other sources (pig and chicken dust in Northern Ireland).
bMLVA patterns were only determined for Typhimurium isolates.
clymph nodes and carcasses in slaughterhouses. Most isolates were serovar Infantis.